Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mipeginterferon alfa-2b + pevifoscorvir sodium
- Development stage
- Unknown
- Lead developer
- Aligos Therapeutics
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Pegbin + ACT580 is a combination regimen consisting of mipeginterferon alfa-2b (Pegbin), a long-acting pegylated interferon-alpha, and pevifoscorvir sodium (ACT580/ALG-000184), an oral small molecule capsid assembly modulator (CAM-E). Developed through a clinical collaboration between Xiamen Amoytop Biotech and Aligos Therapeutics, this combination is being evaluated for the treatment of chronic hepatitis B virus (HBV) infection. Mipeginterferon alfa-2b acts as an immunomodulator and antiviral agent by binding to the interferon-alpha/beta receptor (IFNAR), while pevifoscorvir sodium selectively targets the HBV core protein to disrupt capsid assembly, prevent viral replication, and reduce the cccDNA reservoir. Together, the two agents aim to achieve higher rates of functional cure in patients with chronic hepatitis B.
- Brand names
- Pegbing
- Other names
- Pegbin + ACT-580Pegbin + ACT580Pegbin + ALG-000184Pegbing + ACT-580Pegbing + ACT580Pegbing + ALG-000184mipeginterferon alfa-2b + pevifoscorvir
02
Targets
HBc (Hepatitis B virus core protein)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on mipeginterferon alfa-2b + pevifoscorvir sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mipeginterferon alfa-2b + pevifoscorvir sodium.